These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

440 related articles for article (PubMed ID: 29319354)

  • 1. Inhibition of the RhoA/Rho-associated, coiled-coil-containing protein kinase-1 pathway is involved in the therapeutic effects of simvastatin on pulmonary arterial hypertension.
    Liu WH; Xu XH; Luo Q; Zhang HL; Wang Y; Xi QY; Zhao ZH; Liu ZH
    Clin Exp Hypertens; 2018; 40(3):224-230. PubMed ID: 29319354
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Simvastatin suppresses self-renewal of mouse embryonic stem cells by inhibiting RhoA geranylgeranylation.
    Lee MH; Cho YS; Han YM
    Stem Cells; 2007 Jul; 25(7):1654-63. PubMed ID: 17464088
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Simvastatin prevents and reverses chronic pulmonary hypertension in newborn rats via pleiotropic inhibition of RhoA signaling.
    Wong MJ; Kantores C; Ivanovska J; Jain A; Jankov RP
    Am J Physiol Lung Cell Mol Physiol; 2016 Nov; 311(5):L985-L999. PubMed ID: 27694473
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fluoxetine inhibits monocrotaline-induced pulmonary arterial remodeling involved in inhibition of RhoA-Rho kinase and Akt signalling pathways in rats.
    Wang HM; Wang Y; Liu M; Bai Y; Zhang XH; Sun YX; Wang HL
    Can J Physiol Pharmacol; 2012 Nov; 90(11):1506-15. PubMed ID: 23181278
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Simvastatin Increases Fibulin-2 Expression in Human Coronary Artery Smooth Muscle Cells via RhoA/Rho-Kinase Signaling Pathway Inhibition.
    Serra N; Rosales R; Masana L; Vallvé JC
    PLoS One; 2015; 10(7):e0133875. PubMed ID: 26207907
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Protective effects of aloperin on monocroline-induced pulmonary hypertension via regulation of Rho A/Rho kinsase pathway in rats.
    Wu F; Yao W; Yang J; Zhang M; Xu Y; Hao Y; Yan L; Niu Y; Sun T; Yu J; Zhou R
    Biomed Pharmacother; 2017 Nov; 95():1161-1168. PubMed ID: 28926926
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Simvastatin ameliorates rat cerebrovascular remodeling during hypertension via inhibition of volume-regulated chloride channel.
    Liu YJ; Wang XG; Tang YB; Chen JH; Lv XF; Zhou JG; Guan YY
    Hypertension; 2010 Sep; 56(3):445-52. PubMed ID: 20644009
    [TBL] [Abstract][Full Text] [Related]  

  • 8. LncRNA-SMILR modulates RhoA/ROCK signaling by targeting miR-141 to regulate vascular remodeling in pulmonary arterial hypertension.
    Lei S; Peng F; Li ML; Duan WB; Peng CQ; Wu SJ
    Am J Physiol Heart Circ Physiol; 2020 Aug; 319(2):H377-H391. PubMed ID: 32559140
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Statins suppress MMP2 secretion via inactivation of RhoA/ROCK pathway in pulmonary vascular smooth muscles cells.
    Li M; Li Z; Sun X
    Eur J Pharmacol; 2008 Sep; 591(1-3):219-23. PubMed ID: 18619957
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Simvastatin reduces lipoprotein-associated phospholipase A2 in lipopolysaccharide-stimulated human monocyte-derived macrophages through inhibition of the mevalonate-geranylgeranyl pyrophosphate-RhoA-p38 mitogen-activated protein kinase pathway.
    Song JX; Ren JY; Chen H
    J Cardiovasc Pharmacol; 2011 Feb; 57(2):213-22. PubMed ID: 21052011
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rho-dependent inhibition of the induction of connective tissue growth factor (CTGF) by HMG CoA reductase inhibitors (statins).
    Eberlein M; Heusinger-Ribeiro J; Goppelt-Struebe M
    Br J Pharmacol; 2001 Aug; 133(7):1172-80. PubMed ID: 11487529
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Protective effects of 18β-glycyrrhetinic acid on pulmonary arterial hypertension via regulation of Rho A/Rho kinsase pathway.
    Zhang M; Chang Z; Zhang P; Jing Z; Yan L; Feng J; Hu Z; Xu Q; Zhou W; Ma P; Hao Y; Zhou R
    Chem Biol Interact; 2019 Sep; 311():108749. PubMed ID: 31325423
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Simvastatin alleviates hyperpermeability of glomerular endothelial cells in early-stage diabetic nephropathy by inhibition of RhoA/ROCK1.
    Peng H; Luo P; Li Y; Wang C; Liu X; Ye Z; Li C; Lou T
    PLoS One; 2013; 8(11):e80009. PubMed ID: 24244596
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dietary Geranylgeranyl Pyrophosphate Counteracts the Benefits of Statin Therapy in Experimental Pulmonary Hypertension.
    Zhu L; Liu F; Hao Q; Feng T; Chen Z; Luo S; Xiao R; Sun M; Zhang T; Fan X; Zeng X; He J; Yuan P; Liu J; Ruiz M; Dupuis J; Hu Q
    Circulation; 2021 May; 143(18):1775-1792. PubMed ID: 33660517
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combined effects of the ATP-sensitive potassium channel opener pinacidil and simvastatin on pulmonary vascular remodeling in rats with monocrotaline-induced pulmonary arterial hypertension.
    Jiang L; Zhou T; Liu H
    Pharmazie; 2012 Jun; 67(6):547-52. PubMed ID: 22822545
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HMG-CoA reductase regulates CCL17-induced colon cancer cell migration via geranylgeranylation and RhoA activation.
    Al-Haidari AA; Syk I; Thorlacius H
    Biochem Biophys Res Commun; 2014 Mar; 446(1):68-72. PubMed ID: 24582560
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Simvastatin reduces human atrial myofibroblast proliferation independently of cholesterol lowering via inhibition of RhoA.
    Porter KE; Turner NA; O'Regan DJ; Balmforth AJ; Ball SG
    Cardiovasc Res; 2004 Mar; 61(4):745-55. PubMed ID: 14985071
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Simvastatin ameliorates angiotensin II-induced endothelial dysfunction through restoration of Rho-BH4-eNOS-NO pathway.
    Zhang Z; Wang M; Xue SJ; Liu DH; Tang YB
    Cardiovasc Drugs Ther; 2012 Feb; 26(1):31-40. PubMed ID: 22083280
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Endothelial nitric oxide synthase-enhancing G-protein coupled receptor antagonist inhibits pulmonary artery hypertension by endothelin-1-dependent and endothelin-1-independent pathways in a monocrotaline model.
    Liu CP; Dai ZK; Huang CH; Yeh JL; Wu BN; Wu JR; Chen IJ
    Kaohsiung J Med Sci; 2014 Jun; 30(6):267-78. PubMed ID: 24835346
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Attenuation of monocrotaline-induced pulmonary arterial hypertension in rats by rosuvastatin.
    Li XL; Guan RJ; Li JJ
    J Cardiovasc Pharmacol; 2012 Aug; 60(2):219-26. PubMed ID: 22592772
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.